Nimenrix stability correction
A correction has been made to the summary of product characteristics for Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine; GlaxoSmithKline). The drug is only stable for 8 hours after reconstitution, not 24 hours as was previously stated.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066655
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com